sarpogrelate has been researched along with Kidney Diseases in 2 studies
sarpogrelate: structure given in first source
Kidney Diseases: Pathological processes of the KIDNEY or its component tissues.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Sarpogrelate is a selective 5-hydroxytryptamine receptor subtype 2A (5-HT2A) antagonist." | 2.42 | Sarpogrelate: cardiovascular and renal clinical potential. ( Doggrell, SA, 2004) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (50.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Park, K | 1 |
| Chung, WY | 1 |
| Seo, JB | 1 |
| Kim, SH | 1 |
| Zo, JH | 1 |
| Kim, MA | 1 |
| Park, YB | 1 |
| Doggrell, SA | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Phase 4 Study of Sarpogrelate That Prevent Contrast-induced Nephropathy[NCT01165567] | Phase 4 | 212 participants (Anticipated) | Interventional | 2009-12-31 | Active, not recruiting | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
1 review available for sarpogrelate and Kidney Diseases
| Article | Year |
|---|---|
Sarpogrelate: cardiovascular and renal clinical potential.
Topics: Animals; Cardiovascular Diseases; Humans; Kidney Diseases; Molecular Structure; Succinates | 2004 |
1 trial available for sarpogrelate and Kidney Diseases
| Article | Year |
|---|---|
The prevention of contrast induced nephropathy by sarpogrelate in patients with chronic kidney disease: a study protocol for a prospective randomized controlled clinical trial.
Topics: Adult; Aged; Aged, 80 and over; Chronic Disease; Clinical Protocols; Contrast Media; Humans; Kidney | 2010 |